Abstract:Chimeric antigen receptor (CAR) T-cell therapy has proven a breakthrough in cancer treatment in the last decade, giving unprecedented results against hematological malignancies. All approved CAR T-cell products, as well as many being assessed in clinical trials, are generated using viral vectors to deploy the exogenous genetic material into T-cells. Viral vectors have a long-standing clinical history in gene delivery, and thus underwent iterations of optimization to improve their efficiency and safety. Nonetheless, their capacity to integrate semi-randomly into the host genome makes them potentially oncogenic via insertional mutagenesis and dysregulation of key cellular genes. Secondary cancers following CAR T-cell administration appear to be a rare adverse event. However several cases documented in the last few years put the spotlight on this issue, which might have been underestimated so far, given the relatively recent deployment of CAR T-cell therapies. Furthermore, the initial successes obtained in hematological malignancies have not yet been replicated in solid tumors. It is now clear that further enhancements are needed to allow CAR T-cells to increase long-term persistence, overcome exhaustion and cope with the immunosuppressive tumor microenvironment. To this aim, a variety of genomic engineering strategies are under evaluation, most relying on CRISPR/Cas9 or other gene editing technologies. These approaches are liable to introduce unintended, irreversible genomic alterations in the product cells. In the first part of this review, we will discuss the viral and non-viral approaches used for the generation of CAR T-cells, whereas in the second part we will focus on gene editing and non-gene editing T-cell engineering, with particular regard to advantages, limitations, and safety. Finally, we will critically analyze the different gene deployment and genomic engineering combinations, delineating strategies with a superior safety profile for the production of next-generation CAR T-cell.

CRISPR-Cas gene knockouts to optimize engineered T cells for cancer immunotherapy

Genetically engineered T cells for cancer immunotherapy

CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

Gene editing technology to improve antitumor T-cell functions in adoptive immunotherapy

Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapy

CRISPR–Cas9 applications in T cells and adoptive T cell therapies

Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy

CRISPR/Cas9-Mediated Customizing Strategies for Adoptive T-Cell Therapy

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology

CRISPR, CAR-T, and NK: Current applications and future perspectives

Building Potent Chimeric Antigen Receptor T Cells with CRISPR Genome Editing

Therapeutic potential of CRISPR/CAS9 genome modification in T cell-based immunotherapy of cancer

Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy

Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons

Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR system

A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies

Unlocking the potential of Tregs: innovations in CAR technology

Tuning CAR T-cell therapies for efficacy and reduced toxicity

Engineering strategies to safely drive CAR T-cells into the future